Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503204 · ClinicalTrials.gov registry record · Phase 1
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00503204 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 20 participants.
The verdict
NCT00503204, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
Interventions
- DRUG Lomustine
- DRUG Cediranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503204
The ClinicalTrials.gov registry entry for NCT00503204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lomustine is the first listed.
NCT00503204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503204 about?
NCT00503204 is a clinical study titled "Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour". This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
What is the current status of trial NCT00503204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00503204?
The interventions under investigation include: Lomustine (DRUG), Cediranib (DRUG).
Who is sponsoring clinical trial NCT00503204?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.